NDA submission to the FDA marks a pivotal step toward U.S. market entry, while profitability improved despite flat group sales. Strong growth in Spain, France, and the U.K. offset a sharp decline in Germany, and a new credit facility strengthens financial flexibility during the FDA review.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.